{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:48:01Z","timestamp":1790480881224,"version":"4.1.0"},"reference-count":32,"publisher":"EDP Sciences","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1051\/medsci\/200925121135","type":"journal-article","created":{"date-parts":[[2011,3,3]],"date-time":"2011-03-03T10:02:37Z","timestamp":1299146557000},"page":"1135-1140","source":"Crossref","is-referenced-by-count":5,"title":["Les complications infectieuses li\u00e9es \u00e0 l\u2019utilisation des anticorps monoclonaux chez l\u2019homme"],"prefix":"10.1051","volume":"25","author":[{"given":"\u00c9milie","family":"Rigal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gateault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvon","family":"Lebranchu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hoarau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"250","published-online":{"date-parts":[[2009,12,15]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy.Nature1988; 332 : 323\u20137.","DOI":"10.1038\/332323a0"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"N\u00fcckel H, Frey UH, R\u00f6th A, D\u00fchrsen U, Siffert W. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.Eur J Pharmacol2005; 514 : 217\u201324.","DOI":"10.1016\/j.ejphar.2005.03.024"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Osterborg A, Dyer MJ, Bunjes D,et al.Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.J Clin Oncol1997; 15 : 1567\u201374.","DOI":"10.1200\/JCO.1997.15.4.1567"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Rai KR, Freter CE, Mercier RJ,et al.Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.J Clin Oncol2002; 20 : 3891\u20137.","DOI":"10.1200\/JCO.2002.06.119"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Keating MJ, Flinn I, Jain V,et al.Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.Blood2002; 99 : 3554\u201361.","DOI":"10.1182\/blood.V99.10.3554"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Martin SI, Marty FM, Fiumara K,et al.Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.Clin Infect Dis2006; 43 : 16\u201324.","DOI":"10.1086\/504811"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Peleg AY, Husain S, Kwak EJ,et al.Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.Clin Infect Dis2007; 44 : 204\u201312.","DOI":"10.1086\/510388"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Osterborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H. Strategies in the management of alemtuzumab-related side effects.Semin Oncol2006; 33 : S29\u201335.","DOI":"10.1053\/j.seminoncol.2006.01.027"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Walker AR, Kleiner A, Rich L,et al.Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.Cancer Invest2008; 26 : 431\u20133.","DOI":"10.1080\/07357900701809068"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials.Cancer2007; 109 : 2182\u20139.","DOI":"10.1002\/cncr.22666"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Schulz H, Bohlius JF, Trelle S,et al.Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.J Natl Cancer Inst2007; 99 : 706\u201314.","DOI":"10.1093\/jnci\/djk152"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Kaplan LD, Lee JY, Ambinder RF,et al.Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.Blood2005; 106 : 1538\u201343.","DOI":"10.1182\/blood-2005-04-1437"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Bou\u00e9 F, Gabarre J, Gisselbrecht C,et al.Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin\u2019s lymphoma.J Clin Oncol2006; 24 : 4123\u20138.","DOI":"10.1200\/JCO.2005.05.4684"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Goldberg SL, Pecora AL, Alter RS,et al.Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab.Blood2002; 99 : 1486\u20138.","DOI":"10.1182\/blood.V99.4.1486"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Suzan F, Ammor M, Ribrag V,et al.Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder.N Engl J Med2001; 345 : 1000.","DOI":"10.1056\/NEJM200109273451315"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Vallet S, Tempescul A, Tran A,et al.Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab.Ann Hematol2005; 84 : 545\u20137.","DOI":"10.1007\/s00277-005-1038-0"},{"key":"R17","unstructured":"Carson KR, Evens AM, Richey EA,et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood2009; 113 : 4834\u201340."},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Niscola P, Del Principe MI, Maurillo L,et al.Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy.Leukemia2005; 19 : 1840\u20131.","DOI":"10.1038\/sj.leu.2403914"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Perceau G, Diris N, Estines O,et al.Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.Br J Dermatol2006; 155 : 1053\u20136.","DOI":"10.1111\/j.1365-2133.2006.07451.x"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.N Engl J Med2001; 344 : 68\u20139.","DOI":"10.1056\/NEJM200101043440120"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Tsutsumi Y, Tanaka J, Kawamura T,et al.Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin\u2019s lymphoma.Ann Hematol2004; 83 : 58\u201360.","DOI":"10.1007\/s00277-003-0748-4"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Aksoy S, Harputluoglu H, Kilickap S,et al.Rituximab-related viral infections in lymphoma patients.Leuk Lymphoma2007; 48 : 1307\u201312.","DOI":"10.1080\/10428190701411441"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.Ann Oncol2006; 17 : 1424\u20137.","DOI":"10.1093\/annonc\/mdl141"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Dixon WG, Watson K, Lunt M,et al.Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. British Society for Rheumatology Biologics Register.Arthritis Rheum2006; 54 : 2368\u201376.","DOI":"10.1002\/art.21978"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ,et al.Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.JAMA2006; 295 : 2275\u201385.","DOI":"10.1001\/jama.295.19.2275"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.Arthritis Rheum2004; 50 : 1740\u201351.","DOI":"10.1002\/art.20311"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Schiff MH, Burmester GR, Kent JD,et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis2006; 65 : 889\u201394.","DOI":"10.1136\/ard.2005.043166"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Reino JJ, Carmona L, Valverde VR,et al.Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.Arthritis Rheum2003; 48 : 2122\u20137.","DOI":"10.1002\/art.11137"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.N Engl J Med2005; 353 : 375\u201381.","DOI":"10.1056\/NEJMoa051847"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.N Engl J Med2005; 353 : 369\u201374.","DOI":"10.1056\/NEJMoa051782"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Van Assche G, Van Ranst M, Sciot R,et al.Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease.N Engl J Med2005; 353 : 362\u20138.","DOI":"10.1056\/NEJMoa051586"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Carson KR, Focosi D, Major EO,et al.Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.Lancet Oncol2009; 10 : 816\u201324.","DOI":"10.1016\/S1470-2045(09)70161-5"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/200925121135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T23:44:15Z","timestamp":1560037455000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/200925121135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":32,"journal-issue":{"issue":"12"},"alternative-id":["medsci20092512p1135"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/200925121135","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}